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Introduction

49
Scavenger Receptor Class B Type I (SR-BI) is a 509 amino acid cell surface receptor with a large 50 extracellular loop and short intracytoplasmic amino-and carboxy -termini (8 and 45 amino acids long 51 respectively) (49) that is most highly expressed in the liver and in the steroidogenic cells of the adrenal 52 gland, testes and ovary (1). A minor mRNA splicing isoform, SR-BII with a different C-terminus (39 53 residues replace 45 in SR-BI) has been described (68). As a high density lipoprotein (HDL) receptor, SR-54 BI plays an important role in the transfer of cholesterol from HDL particles to cells (1, 49), controls HDL 55 abundance and structure in both mice (50) (50% C57BL/6/50% 129-S4 background) and humans (59, 65, 56 79), serves as a signaling receptor to control eNOS activity and vascular tone (77) and is a co-receptor for 57 hepatitis C virus (8) and malaria (51, 69) . Inactivation of murine SR-BI (SR-BI knockout (KO) mice) 58 results in a 2.2-fold increase of plasma cholesterol in abnormally large HDL particles with an abnormally 59 high ratio of unesterified to total cholesterol (UC:TC) (5, 50, 63) . Analyses of SR-BI KO mice (50) and 60 mice with hepatic overexpression of 73) have established that SR-BI can influence a variety of 61 physiologic and pathophysiologic systems, including red blood cell maturation and stability (25), platelet 62 stability and function (13), biliary cholesterol secretion (35, 39) , reverse cholesterol transport (83), 63 steroidogenesis (37, 58), female fertility (41, 61, 72) , deep vein thrombosis (6), and 64 atherosclerosis/coronary heart disease (4, 61). 65
The expression, localization and function of SR-BI and many other membrane proteins can be 66 regulated by cytoplasmic adaptor proteins (34, 74) . A large group of such cytoplasmic proteins consists of 67 the PDZ (PSD-95, Discs-large, ZO-1) domain protein family (64). PDZ domains are globular structures 68 of 80-90 amino acids; usually interacting with the carboxy terminal amino acids of their target protein 69 using a well-defined binding pocket, although some PDZ domains can recognize internal peptide 70 sequences (14, 22, 46) and some bind to anionic lipids in the cytoplasmic leaflets of cellular membranes 71 (9, 62, 85) . More than 100 PDZ domain-containing proteins have been described in humans, many of 72 which contain multiple PDZ domains that allow them to function as scaffolds to bring together their 73 target proteins/membranes for signal transduction and complex cellular functions (31, 64, 70) . One of 74 these multi-PDZ-domain adaptor proteins, PDZK1, is 519 amino acids long, contains four PDZ domains 75
and interacts with several membrane-associated proteins, mostly ion channels (31, 32).
76
One of PDZK1's target proteins is the HDL receptor SR-BI. PDZK1was first shown to interact 77 with the carboxy terminus of SR-BI by Ikemoto et al. (27) and was the first described tissue-specific 78 adaptor protein of SR-BI (33). The carboxy terminus of SR-BI binds to either the first (PDZ1, high 79 affinity interaction) or the third (PDZ3, low affinity interaction) PDZ domain of PDZK1 (27, 29, 30) . The 80 five C-terminal residues of SR-BI (
505
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509
) form hydrogen bonds and hydrophobic contacts with 81 the canonical peptide binding pockets in these two PDZ domains (29, 30) . The PDZ4 domain of PDZK1 82 also is required for full hepatic expression of SR-BI protein. PDZ4 appears to function by mediating 83 PDZK1 binding directly to lipids in the inner leaflet of the plasma membrane rather than by canonical 84 binding to the C-terminus of a target protein (62). Thus bidentate binding of PDZK1 to both SR-BI and 85 membrane lipids is essential for normal hepatic SR-BI expression. This regulation influences the 86 intracellular localization of SR-BI as well as the amount of SR-BI protein, presumably in part as a 87 consequence of reduced protein stability. The results of these and other structure/function studies of the 88 role of PDZK1 in regulating SR-BI are summarized in (62).
89
In hepatocytes, PDZK1 post-transcriptionally controls the expression, localization and function of 90 SR-BI (33). In PDZK1 KO mice (129SvEv genetic background), hepatic SR-BI protein is reduced by 91 95% compared to wild-type controls. As a consequence there is increased plasma cholesterol (1.7 fold) in 92 the form of abnormally large HDL particles, a phenotype similar to, but not as severe as, that in SR-BIterminal cytoplasmic residues, most likely because those residues are required for binding to a distinct 116 cytoplasmic adaptor required to maintain normal receptor levels.
117
We compared a variety of characteristics of SR-BIΔCT mice to those of WT, SR-BI KO and 118 PDZK1 KO mice, including composition and size of the HDL, female fertility, red blood cell (RBC) and 119 platelet levels, cholesteryl ester (CE) stores in steroidogenic cells, and atherosclerosis and coronary heart 120 disease susceptibility when combined with apoE deficiency. For some phenotypes, the SR-BIΔCT mice 121 resembled WT mice (female fertility, RBC and platelets, CE stores). Other phenotypes of SR-BIΔCT 122 mice resembled those of either SR-BI KO or PDZK1 KO mice (plasma lipoprotein composition and size, 123 atherosclerosis and coronary heart disease susceptibility). For example, when SR-BIΔCT mice were 124 crossed with apolipoprotein E knockout mice (apoE KO), the SR-BIΔCT/apoE mice fed a standard chow 125 died exhibited early onset, fatal atherosclerotic coronary heart disease (CHD), and thus provide a novel 126 model for the study of CHD. 127
Material and Methods
128
Generation of SR-BIΔCT Knock-in mice: A SR-BIΔCT Knock-in mouse containing a deletion 129 of the last three carboxy terminal amino acids of SR-BI was generated by Ingenious Targeting Laboratory 130 (Fig. 1A) . and SR-BIΔCT mice (both on a mixed C57BL/6 X 129S2/SvCrl (37.5:62.5) genetic background, see 154 above) were maintained on a normal chow diet. Six to ten week old male and female mice were used for 155 experiments. For atherosclerosis studies, apoE deficient mice (C57BL/6 background) (82) were purchased 156 from Jackson Laboratories (Bar Harbor, ME), mated with the SR-BIΔCT mice and maintained on a 157 standard chow diet. Genotypes were determined by PCR using established protocols (see above and 158
Jackson Laboratories web site). After the initial breeding, apoE KO mice heterozygous for the SR-159 BIΔCT mutation and apoE KO were mated to generate apoE KO and SR-BIΔCT/apoE KO mice with the 160 same proportion of C57/B6 and 129 backgrounds (68.75:31.25, respectively) 
Results
229
Role of the carboxy terminus of SR-BI on the regulation of SR-BI protein expression and 230 function.
231
To determine the impact of the absence of the three carboxy terminal (CT) amino acids of SR-BI 232 on its regulation in the liver and in steroidogenic organs, and the influence of the truncated protein on SR-233 BI-dependent physiology and pathophysiology, we used Knock-in technology to modify the endogenous 234 mouse SR-BI gene so that the SR-BI protein would contain a deletion ("ΔCT") of the last three C-235 terminal amino acids (residues 507 AKL 509 ) by replacing the codon for 507 Ala in exon 12 with a Stop codon 236 (Fig.1A ). The ΔCT mutation was designed to prevent the interaction of the C-terminus of SR-BI with 237 cytoplasmic adaptors that recognize the C-terminal residues, such as the PDZ1 and PDZ3 domains in 238 PDZK1 (29, 30). Mice homozygous for this deletion mutation, designated SR-BIΔCT, were generated 239 and have been observed for one year. They develop normally, and show no alteration in gross 240 morphology, weight and size compared to wild-type mice. These mice and their wild-type (WT) controls 241 used for the experiments reported here are on a mixed C57BL/6:129S2/SvCrl (37.5:62.5) genetic 242 background.
243
Effects of the SR-BIΔCT mutation on SR-BI mRNA and protein expression in the liver. The 244 expression levels in the livers of WT and SR-BIΔCT mice of the mRNA for SR-BI and its minor splice 245 isoform SR-BII were evaluated by qPCR. We used oligonucleotide primers that either recognized both 246 SR-BI and its minor splice isoform SR-BII or that were specific for the SR-BII isoform only (see 247
Materials and Methods). Steady state levels of receptor protein were measured by quantitative 248 immunoblot analysis using three specific antibodies: an anti-C-terminus antipeptide antibody (anti-SR-249 BI 495-112 ) (1, 16) that recognizes SR-BI, but not SR-BII, whose C-terminus differs from that of SR-BI 250 (68). A commercial anti-C-terminus antipeptide antibody (Novus) that recognizes SR-BII, but not SR-BI, 251 and the polyclonal antibody KKB-1 (19) that recognizes the extra-cellular loops of both SR-BI and SR-252 BII (33, 68). The KKB-1 antibody is the only one of these three expected to recognize SR-BIΔCT.
253
The qPCR analysis established that the truncated receptor's mRNA copy number (expressed as 254 "n" copies/10 6 copies of 18S rRNA, see Materials and Methods) in SR-BIΔCT liver was similar to that of 255 full-length SR-BI in WT liver (WT: 48.0±2.8; ΔCT: 40.5±0.9; ~16% reduction, p=0.04). This small 256 difference might be due to reduced transcription, stability or both. The copy number of the mRNA for the 257 minor splice variant SR-BII was low in WT liver (6.3±0.4) and unexpectedly increased by 2.5 fold in SR-258 BIΔCT livers (15.9±0.9, p<0.0001).
259
As demonstrated in Fig. 2A , top panel, the anti-C-terminus anti-SR-BI 495-112 antibody (anti-C-260 term) could readily detect a band corresponding to SR-BI (~82 kDa) in WT liver (and adrenal gland and 261 ovary, see below), but not in tissues from SR-BIΔCT mice carrying the C-terminal, three-residue deletion.
262
An antibody to the cytosolic COPI coat subunit ε-COP was used as a loading control (bottom panel). The 263 absence of signal in the SR-BIΔCT-tissues is likely due to the inability of the anti-C-terminus antibody to 264 recognize the SR-BIΔCT protein or the complete absence of this protein. Using the KKB-1 antibody, 265 which does not require an intact C-terminus to detect SR-BI or SR-BII, a strong signal could be seen in 266 the immunoblot of WT livers ( Fig. 2A , middle panel, left), but there was a more than a 95% reduction in 267 the signal in livers from SR-BIΔCT mice (the relative expression -SR-BIΔCT/WT-was 0.03±0.003 268 (p<0.0001) (Fig. 2C , left panel). These results were confirmed by immunohistochemical localization of 269 receptors using the KKB-1 antibody. There was robust staining of the sinusoidal membranes of 270 hepatocytes in WT liver (Fig. 2D ), but no significant staining in SR-BIΔCT liver (Fig. 2D) A small amount of the receptor protein in SR-BIΔCT adrenal glands and ovaries detected using 320 the KKB-1 antibody (Fig. 3A, 2nd panel, left and right) is likely to have been contributed by the minor 321 isoform SR-BII. When a SR-BII-specific, antipeptide antibody was used for immunoblotting (Fig. 3A, 4th  322 panel) the relatively weak intensities for SR-BII in both WT tissues were increased in SR-BIΔCT tissues, 323 9.2±2.2-fold (p=0.02) in adrenal glands and 2.7±0.3-fold (p=0.003) in the ovaries (Fig. 3A, fourth panel) . 324
The increased SR-BII protein expression might have been due, at least in part, to the increase in SR-BII 325 mRNA, increased translation or increased protein stability, or some combination of these. Despite the 326 increase in SR-BII protein in these steroidogenic tissues in SR-BIΔCT compared to WT mice, the overall 327 levels of both isoforms of this receptor detected by the KKB-1 antibody were substantially lower (84%) in 328 SR-BIΔCT mice compared to WT mice (Fig. 3A, 2nd panel, center and right). These results differed 329 dramatically from those in PDZK1 KO mice in which there is essentially no loss of SR-BI protein 330 expression in steroidogenic tissues compared to WT mice (33). Based on these results, we propose that 331 the steroidogenic cells in the adrenal glands and ovaries, and possibly the testes, express an adaptor 332 protein(s) that is functionally similar to PDZK1 in hepatocytes in that it recognizes the C-terminal three 333 residues of SR-BI and is required for expression of normal SR-BI protein levels in thesecells.
334
Functional consequences of the SR-BIΔCT mutation in SR-BIΔCT KI mice. 335
Plasma cholesterol and lipoproteins in SR-BIΔCT mice. Figure 4A shows a comparison of the 336 plasma levels of total (unesterified plus esterified, Fig. 4A -a) and unesterified cholesterol ( Fig.4A-b an increase in the UC:TC ratio in SR-BIΔCT mice (Fig. 4A-c (Fig. 5B ). These 389 qualitative histochemical results were confirmed quantitatively in adrenal glands when we measured the 390 total cholesterol content of adrenal glands from male and female (n=6 in each group) WT and SR-BIΔCT 391 mice. In female mice, there was no statistically significant difference (p>0.05) in adrenal gland total 392 cholesterol content between WT and SR-BIΔCT mice (98.67 ± 6.33 and 109.6 ± 6.88 μg cholesterol/mg 393 protein, respectively). The total cholesterol content of the adrenal glands from SR-BIΔCT male mice 394 (99.23 ± 4.44 μg cholesterol/mg protein) was similar to that of their female counterparts (p>0.05). As 395 previously described (57, 66), we observed a significant difference in adrenal gland total cholesterol 396 between male and female WT mice (53.55 ± 3.90 and 98.67 ± 6.33 μg cholesterol/mg protein 397 respectively, p<0.0001). The mechanism(s) responsible for this sexual dimorphisim in WT mice remains 398 uncertain.
399
Although there was a reduction of cell surface HDL receptor protein in the adrenal glands, 400 ovaries and testes of SR-BIΔCT KI mice compared to WT mice (Fig. 3) , the residual levels of receptor 401 apparently were sufficient to maintain nearly normal cholesteryl ester stores. While clearly less than that 402 in WT adrenal glands, those residual receptor levels presumably were adequate to maintain the stores 403 under non-stressed conditions. Cai et al. and Hoekstra et al. have shown that adrenal insufficiency 404 develops in stressed SR-BI KO mice (7, 23) . Future studies will be required to assess the influence of 405 stress on adrenal cortical cholesteryl ester stores and adrenal function in the SR-BIΔCT mice.
406
Influence of the SR-BIΔCT mutation on atherosclerosis and coronary heart disease (CHD).
407
The apoE KO mouse is a standard model used to study aortic root and aortic atherosclerosis, but typically 408 does not develop robust coronary arterial atherosclerosis or CHD during the first 4 months of life (44).
409
To assess the effects of the SR-BIΔCT mutation on atherosclerosis, CHD and cardiac physiology, 410
we crossed the SR-BIΔCT mice with apoE KO mice to obtain two mouse populations with matching 411 genetic backgrounds (C57BL/6:129S2/SvCrl (68.75:31.25)): SR-BIΔCT/apoE KO mice and their apoE 412 KO controls. Both were maintained on a standard lab chow diet for all of the studies described below.
413
Analysis of the plasma from these mice showed that there was a significant 1.6 fold increase in 414 total plasma cholesterol in SR-BIΔCT/apoE KO mice (there was no difference between males and 415 females, therefore the data were combined) compared to apoE KO mice (SR-BIΔCT/apoE KO: 978±61 416 mg/dl, apoE KO: 603±32 mg/dl, p=0.0004) (Fig. 6A-a) . In addition, there was a 276% increase in the 417 UC:TC ratio in SR-BIΔCT/apoE KO compared to apoE KO mice (SR-BIΔCT/apoE KO: 0.83±0.02, apoE 418 KO: 0.30±0.01, p<0.0001) (Fig. 6A-b 7A-c and 7A-g). As one would expect given the occlusive coronary arterial atherosclerosis, trichrome 434 staining of myocardial sections from SR-BIΔCT/apoE KO mice (9 weeks of age) showed evidence of 435 myocardial infarction (MI, fibrosis stained blue, normal myocardium red, Fig. 7A-f ), while no fibrosis 436 was observed in the corresponding apoE KO mice ( Fig. 7A-e) .
437
There were three pathological phenotypes in SR-BIΔCT/apoE KO mice not observed in apoE KO 438 mice that were likely consequences of the occlusive coronary arterial atherosclerosis and MI. The first is 439 cardiomegaly (Fig. 7B) . The hearts in SR-BIΔCT/apoE KO mice (8.24±0.67 mg/g body weight) were 440 abnormally large compared to those of apoE KO (5.21±0.14 mg/g body weight, p<0.0001). There was no 441 statistical difference in the heart:body weight ratios of apoE KO, WT (5.40±0.26 mg/g body weight) and 442 SR-BIΔCT (5.98±0.37 mg/g body weight) mice (p=0.08). Second, the SR-BIΔCT/apoE KO hearts 443 exhibited severe cardiac dysfunction/heart failure. We performed hemodynamic studies using the left 444 ventricular pressure volume loop method on two groups of mice that were analyzed separately because 445 they had different genetic backgrounds: group 1: WT and SR-BIΔCT mice (mixed C57BL/6:129S2/SvCrl 446 (37.5:62.5) genetic background); group 2: apoE KO and SR-BIΔCT/apoE KO mice (mixed 447 C57BL/6:129S2/SvCrl (68.75:31.25) genetic background). Comparison of WT and SR-BIΔCT mice 448 (group 1) established that there were no significant differences in maximum and minimum left ventricular 449 volumes, cardiac output, ejection fraction, dP/dt and stroke work (Table 2) . Thus, the SR-BIΔCT 450 mutation alone did not alter these baseline characteristics of heart function. Compared to the control apoE 451 KO hearts, the SR-BIΔCT/apoE KO exhibited significantly lower cardiac output (reduced to 71% of 452 control), ejection fraction (58%) and stroke work (68%) and significantly higher maximum and minimum 453 left ventricular volumes (143% and 183% of control, respectively) ( Table 3 ). The SR-BIΔCT/apoE KO 454 mice also exhibited significantly lower +dP/dt (60% of control) and -dP/dt (66% of control), suggesting 455 both systolic and diastolic dysfunction (Table 3 ). The ejection fractions determined by PV loop 456 measurement were highly reproducible; however, they were somewhat lower than previously reported for 457 mice (10, 45) . We believe that the lower values are probably a consequence of our using in the present 458 study significantly younger mice (7 weeks old) that those used previously (typically 14-16 weeks old).
459
We analyzed cardiac function in very young mice because the SR-BIΔCT/apoE KO died prematurely 460 (Fig. 7C) , presumably because of heart failure. The SR-BIΔCT/apoE KO mice began to die at 28 days of 461 age, half were dead by 63 days of age and all had died by 79 days of age, with the large majority (65%) 462 dying between the 59 th and 69 th days (8.4 and 9.9 weeks) of age. Thus, SR-BIΔCT/apoE KO mice 463 resemble SR-BI/apoE dKO mice in that the chow-fed animals exhibit severe CHD, spontaneously 464 developing occlusive coronary arterial atherosclerosis, MI, heart dysfunction and premature death (4).
465
The mean age of death for SR-BI/apoE dKO mice is 42 days (4), about 21 days earlier than that of SR-466 BIΔCT/apoE KO mice.
467
Hematologic abnormalities in SR-BIΔCT/apoE KO mice. We also examined the consequences 468 of combining the SR-BIΔCT mutation with apoE deficiency on RBCs and platelets, because the RBC and 469 platelet abnormalities in SR-BI KO mice are exacerbated in SR-BI/apoE dKO mice (13, 25) . The results 470 of our hematologic analyses are shown in Table 4 and Fig. 8A . Indeed, SR-BIΔCT/apoE KO mice 471 developed anemia (an hematocrit of 29.0±2.4% that was 66% of that in apoE KO controls, p=0.0014).
472
Their RBCs showed a dramatic increase in size (mean corpuscular volume, MCV) compared to apoE KO 473 (p<0.0001) with abnormal morphology, including macrocytosis, fragmentation and presence of 474 intracellular inclusions (Fig. 8A, b and d ) and there was a 31.0±6.3% reticulocytosis (vs 2.3±0.8% in 475 apoE KO mice, p=0.0012). As a result and as shown in the histological sections in Fig. 8B , both liver and 476 spleen in SR-BIΔCT/apoE KO mice (panels g and h)-but not WT (a and b), SR-BIΔCT (c and d) or apoE 477
KO (e and f) mice -exhibited extra-medullary hematopoiesis, with expansion of the red pulp and virtual 478 disappearance of the white pulp in the spleen. As a consequence there was a dramatic increase in the size 479 of the spleen (11.7 fold) in SR-BIΔCT/apoE KO compared to apoE KO mice (52.6±6.9 vs 4.5±0.3 mg/g 480 body weight, p<0.0001) (Fig. 8C ). An additional hematologic abnormality in SR-BIΔCT/apoE KO mice 481 was thrombocytopenia, with a platelet count decreased by 43% compared to control apoE KO mice 482 (p=0.0004) ( Table 4 ). It seems likely that the substantial elevation of the UC:TC ratio in SR-BIΔCT/apoE 483 KO mice was responsible, at least in part, for their RBC and platelet abnormalities. 484 485
Discussion
486
PDZK1 is a 'tissue specific' adaptor of SR-BI in that in PDZK1 KO mice relative to WT controls, 487 the expression of SR-BI is decreased by 95% in the liver and 50% in intestinal mucosa, but is essentially 488 unchanged in steroidogenic cells (33). We hypothesized that the PDZK1 independence of SR-BI in 489 steroidogenic cells might be a consequence of one or more alternative adapters in those cells that would 490 be functionally analogous to hepatic PDZK1 in that it would bind the C-terminus of SR-BI and would be 491 required to maintain normal SR-BI protein levels. To test this hypothesis, we used homologous 492 recombination 'Knock-in' technology to introduce a 507 Ala/STOP mutation in the SR-BI gene (scarb1) 493 resulting in the deletion of the last three amino acid residues ( 507 AKL 509 ) at the carboxy terminus of SR-BI 494 ("SR-BIΔCT"). This mutation would not alter the structure of the alternatively spliced, minor isoform 495 SR-BII. We call the animals carrying these homozygous Knock-in truncation mutations SR-BIΔCT mice.
496
The mixed genetic backgrounds of the mice generated in this study and the genetic backgrounds of 497 previously described mice to which comparisons are made are provided in Materials and Methods under 498 'Animals'.
499
Based on well-established principles of PDZ domain binding to target peptides (55) and previous 500 studies of mutations in SR-BI, the 507 AKL 509 deletion in SR-BIΔCT will abrogate all receptor activity 501 dependent on C-terminus binding to PDZ domains in PDZK1, but will not alter the surface expression or 502 intrinsic lipid transport activities of SR-BI. The PDZK1-dependent activities include normal SR-BI 503 protein expression in the liver (33), HDL-mediated regulation of endothelial cell physiology (endothelial 504 NO synthase activity, cell migration, reendothelialization following injury (84)) and hepatitis C virus 505 infectivity (8). Intrinsic lipid transport activities include selective lipid (e.g., cholesteryl ester) uptake (1, 506 42, 56), cellular efflux of unesterified cholesterol (28) and altered accessibility of plasma membrane 507 cholesterol (56). For example, deletion of SR-BI's C-terminal L 509 abrogates its binding to PDZK1 and 508 consequent regulation of eNOS activity via a PDZK1-dependent signaling pathway in endothelial cells 509 (2), but does not impair HDL binding and selective lipid uptake in cultured cells (54). Replacement of 510 either the cytoplasmic C-terminal 45 (or 42) residues of SR-BI with the unrelated cytoplasmic C-terminal 511 6 (or 14) residues of CD36, another class B scavenger receptor, does not alter HDL binding or lipid 512 transport (11, 12, 19) . Indeed, truncation of SR-BI's C-terminal 42 residues without replacement also 513 does not alter HDL binding or lipid transport (11). 514
In the current study we found that the C-terminus of SR-BI is required for maintaining normal 515 receptor levels not only in the liver (<5% of normal in SR-BIΔCT mice) but also in the adrenal gland, 516 ovary and testes (e.g., ~84% and ~64% reductions in adrenal gland and ovary, respectively). It is possible 517 that metabolic regulation (52), e.g., cholesterol-stores-mediated suppression of receptor expression (57, 518 66), may have contributed to reduced receptor protein levels in the steroidogenic cells in SR-BIΔCT 519 mice. However, most of the metabolic (cholesterol stores) and hormonal (ACTH) regulation of SR-BI in 520 steroidogenic cells is thought to occur by controlling mRNA levels (e.g., transcriptional control) (52, 57, 521 66) and there was only a very small change in receptor mRNA in the SR-BIΔCT mice compared to WT 522 controls. Thus, we conclude that, as is the case in the liver, the reduction in receptor protein levels in SR-523 BIΔCT mice is primarily a posttranslational process. We propose that, as is the case in the liver with the 524 adaptor protein PDZK1, it is likely that there is an adaptor(s) in steroidogenic cells that is distinct from 525 PDZK1, possibly contains one or more PDZ domains, recognizes SR-BI's C-terminus and mediates stable 526 SR-BI protein expression. The residual levels of receptor protein in the adrenal glands, ovaries and testes 527 in SR-BIΔCT mice were apparently sufficient to maintain nearly normal cholesteryl ester stores in these 528 chow diet-fed mice under standard housing conditions. In contrast, in SR-BI KO mice that express no 529 SR-BI protein, there is a striking reduction in the cholesteryl ester stores in the adrenal glands (24, 49, 50) 530 and ovarian corpora lutea (61). 531 SR-BI is expressed in many tissues at varying levels and our results with steroidogenic cells raise 532 the possibility that adaptors that recognize its C-terminus may play roles in other nonhepatic and 533 nonsteroidogenic cells as well. For example, in intestines, there is a partial dependence of SR-BI 534 expression on PDZK1 (33) -it is possible that an additional C-terminal adaptor(s) together with PDZK1 535 in intestines participates in mediating normal levels of SR-BI expression. Future analyses of receptor 536 expression in other tissues of SR-BIΔCT mice will help address this issue. There is precedent for the 537 activities of a lipoprotein receptor depending on different cytoplasmic adaptors in different types of cells.
538
LDL receptors use at least two different adaptors for clathrin-mediated endocytosis, ARH and Dab2. Both 539 adaptors bind to the receptor's NPXY internalization motif and to phospholipids (18). ARH is required 540 for normal LDL receptor-mediated endocytosis in hepatocytes and lymphocytes, but is not essential for 541 endocytosis in fibroblasts (18, 21, 86) . Apparently both ARH and Dab2 can mediate LDL receptor 542 endocytosis in fibroblasts, with endocytosis dramatically reduced in fibroblasts lacking ARH when Dab2 543 expression is additionally suppressed by siRNA (15, 78) . The identity of the putative adaptor(s) for SR-BI 544 in steroidogenic cells is unknown. Azhar and colleagues have reported that two PDZ domain containing 545 proteins, NHERF1 and NHERF2 have the ability to interact with SR-BI, apparently even when its C-546 terminus is blocked by an epitope tag, and might be involved with the negative regulation of SR-BI in 547 steroidogenic cells (26, 52). As the putative adaptor proposed here is expected to positively regulate SR-548 BI (i.e., reduced SR-BI when the interaction is blocked by the C-terminal deletion), neither NHERF1 nor 549 NHERF2 is likely to be the putative adaptor proposed here. Future studies will be required to identify the 550 putative adaptor for SR-BI in steroidogenic cells.
551
In addition to examining receptor protein levels in the livers and steroidogenic tissues in SR-552 BIΔCT mice, we observed a number of abnormal phenotypes of SR-BIΔCT mice that were intermediate 553 between those of PDZK1 KO mice and SR-BI KO mice. As the SR-BIΔCT, PDZK1 KO and SR-BI KO 554 mice have different genetic backgrounds (see Materials and Methods), caution should be exercised when 555 interpreting some of the phenotypic differences between these mutant mice. The PDZK1 KO mice exhibit 556 limited, tissue specific reduction or loss of SR-BI activity (33), whereas SR-BI KO mice are completely 557 SR-BI/SR-BII negative (50). SR-BI KO, SR-BIΔCT and PDZK1 KO mice are all hypercholesterolemic 558 (2.2-, 2.1-and 1.7-fold plasma cholesterol levels above controls, respectively) with varying amounts of 559 abnormally large HDL particles (32, 33, 50 (40)). SR-BI/apoE dKO mice fed a standard chow diet rapidly develop 591 severe occlusive coronary arterial atherosclerosis, myocardial infarction (MI), heart dysfunction and 592 premature death (death between 5-8 weeks of age, median age of death is 6 weeks) (4, 61). PDZK1/apoE 593 dKO mice exhibit far less severe atherosclerosis-related phenotypes. When PDZK1/apoE dKO mice are 594 fed a moderately atherogenic ('Western') diet for three months, they develop more aortic root 595 atherosclerosis than apoE KO controls, but no occlusive coronary arterial atherosclerosis, MI or very 596 early death (34). When the PDZK1/apoE dKO mice are fed a more severe atherogenic (Paigen-or HFC-597 15.8% fat, 1.25% cholesterol, 0.5% sodium cholate) diet for three months, they not only exhibit more 598 aortic root atherosclerosis than the apoE KO, but also develop some occlusive coronary arterial 599 atherosclerosis and cardiac fibrosis, but do not exhibit premature death (71). 600
In SR-BIΔCT/apoE KO mice fed a standard chow diet, the total cholesterol was 1.6-fold higher 601 than in apoE KO controls and ~5.7-fold higher than in SR-BIΔCT mice, and the UC:TC ratio was 0.83.
602
The SR-BIΔCT/apoE KO mice exhibited severe macrocytic anemia (hematocrit ~66% of control) with 603 abnormal red blood cell morphology, resulting in hepatic and splenic extramedullary hematopoiesis, 604 massive splenomegaly, and marked reticulocytosis (31%), as well as thrombocytopenia (57% of control).
605
In addition, SR-BIΔCT/apoE KO mice rapidly developed extensive aortic root and severe occlusive 606 coronary arterial atherosclerosis, MI, heart dysfunction and failure (assessed by PV loop method) and 607 premature death (median age of death was 9 weeks, 65% died between 8.4 and 9.9 weeks of age). As 608 noted above, our results raise the possibility that reduced levels of receptor activity in extrahepatic tissues 609 in SR-BI/apoE dKO and SR-BIΔCT/apoE KO mice that do not occur in PDZK1/apoE dKO mice may 610 have contributed to severe, lethal coronary heart disease.
611
The SR-BIΔCT/apoE KO mice provide a new addition to the limited collection of mouse models 612 of atherosclerotic coronary heart disease (CHD), e.g., see (4, 80 from WT and SR-BIΔCT six to ten week old mice. Bands were visualized by chemiluminescence, but 962 using exposure times significantly shorter than those used in Fig 2A because of the higher protein 963 expression in these steroidogenic tissues than in the liver. Proteins were detected using an SR-BI-specific 964 (SR-BI (anti-C-term)) antibody, an anti-SR-BI/SR-BII (KKB-1) antibody or an SR-BII-specific (SR-BII 965 (anti-C-term)) antibody, as described in Fig 2. An anti-ε-COP antibody was used as a loading control. B.
966
Relative expression of SR-BI/SR-BII(KKB-1) and SR-BII in WT and SR-BIΔCT (ΔCT) mouse adrenal 967 gland and ovary. *, value significantly different (p<0.0001 for SR-BI/SR-BII(KKB-1) in adrenal glands 968 and p=0.0009 in ovaries and p=0.02 in adrenal glands and p=0.003 in ovaries for SR-BII) . C. Adrenal 969 glands, ovaries and testes from WT and SR-BIΔCT mice were fixed, frozen, sectioned and the sections 970 stained with the polyclonal anti-SR-BI/SR-BII KKB-1 antibody and a biotinylated anti-rabbit IgG 971 secondary antibody, and visualized by immunoperoxidase staining. Results for male and female mouse 972 adrenal glands were identical (Magnification, X300; Bar: 100 µm). 973 
